Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 3
2003 2
2004 4
2005 4
2006 5
2007 8
2008 1
2009 1
2014 2
2015 3
2016 6
2017 6
2018 5
2019 6
2020 2
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean nazzarenodimasi (2 results)?
Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.
Kinneer K, Wortmann P, Cooper ZA, Dickinson NJ, Masterson L, Cailleau T, Hutchinson I, Vijayakrishnan B, McFarlane M, Ball K, Davies M, Lewis A, Huang Y, Rosenbaum AI, Yuan J, Chesebrough J, Anderton J, Monks N, Novick S, Wang J, Dimasi N, Christie RJ, Sabol D, Tosto FA, Wallez Y, Leo E, Albertella MR, Staniszewska AD, Tice DA, Howard PW, Luheshi N, Sapra P. Kinneer K, et al. Among authors: dimasi n. Clin Cancer Res. 2023 Mar 14;29(6):1086-1101. doi: 10.1158/1078-0432.CCR-22-2630. Clin Cancer Res. 2023. PMID: 36355054
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.
Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJ, Bezabeh BZ, Fleming RL, Dimasi N, Feng H, Toader D, Yuan AQ, Xu L, Lin J, Gao C, Wu H, Dixit R, Osbourn JK, Coats SR. Li JY, et al. Among authors: dimasi n. Cancer Cell. 2016 Jan 11;29(1):117-29. doi: 10.1016/j.ccell.2015.12.008. Cancer Cell. 2016. PMID: 26766593 Free article.
MHC class I recognition by Ly49 natural killer cell receptors.
Natarajan K, Dimasi N, Wang J, Margulies DH, Mariuzza RA. Natarajan K, et al. Among authors: dimasi n. Mol Immunol. 2002 May;38(14):1023-7. doi: 10.1016/s0161-5890(02)00031-7. Mol Immunol. 2002. PMID: 11955594 Review.
Straightforward Glycoengineering Approach to Site-Specific Antibody-Pyrrolobenzodiazepine Conjugates.
Thompson P, Ezeadi E, Hutchinson I, Fleming R, Bezabeh B, Lin J, Mao S, Chen C, Masterson L, Zhong H, Toader D, Howard P, Wu H, Gao C, Dimasi N. Thompson P, et al. Among authors: dimasi n. ACS Med Chem Lett. 2016 Sep 20;7(11):1005-1008. doi: 10.1021/acsmedchemlett.6b00278. eCollection 2016 Nov 10. ACS Med Chem Lett. 2016. PMID: 27882199 Free PMC article.
A multifunctional bispecific antibody protects against Pseudomonas aeruginosa.
DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu XQ, Suzich JA, Stover CK. DiGiandomenico A, et al. Among authors: dimasi n. Sci Transl Med. 2014 Nov 12;6(262):262ra155. doi: 10.1126/scitranslmed.3009655. Sci Transl Med. 2014. PMID: 25391481
55 results